Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GENENTECH ADVANCED THE COLLABORATION'S FIRST NEUROSCIENCE TARGET INTO A JOINT EARLY DISCOVERY PROGRAM, PROVIDING EARLY EVIDENCE THAT RECURSION'S PLATFORM CAN GENERATE NOVEL, BIOLOGICALLY VALIDATED TARGETS FOR DRUG DISCOVERY REC-4881 (MEK1/2 INHIBITOR): ADDITIONAL PHASE 2 DATA IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TO BE PRESENTED AT THE PRESIDENTIAL PLENARY SESSION AT LEADING HEREDITARY GI ANNUAL MEETING IN NOVEMBER 2026 REC-7735 (PI3K H1047R INHIBITOR): IND CLEARED, PHASE 1/2 TRIAL START IN 2H26; A >100 MUTANT-SELECTIVE PI3K H1047R INHIBITOR DESIGNED TO IMPROVE THERAPEUTIC INDEX BY ENABLING DEEP SUPPRESSION OF THE MOST COMMON ACTIVATING PI3K MUTATION WHILE SPARING WILD-TYPE PI3K REDUCED 2026 CASH OPERATING EXPENSE GUIDANCE TO 100-FOLD SELECTIVITY FOR THE H1047R MUTANT OVER WILD TYPE IN ORDER TO DRIVE HIGH, SUSTAINED TARGET INHIBITION WHILE AVOIDING HYPERINSULINEMIA-DRIVEN REACTIVATION THE DIFFERENTIATED DEVELOPMENT CANDIDATE WAS DELIVERED IN 10 MONTHS AND 242 COMPOUNDS FROM FIRST NOVEL HIT THROUGH RECURSION'S AI-NATIVE DESIGN PLATFORM, DEMONSTRATING THE COMPANY'S ABILITY TO RAPIDLY TRANSLATE PLATFORM INSIGHTS INTO OPTIMIZED CLINICAL CANDIDATES WITH THE IND CLEARED, THE PHASE 1/2 ZINNIA CLINICAL STUDY FOR PATIENTS WITH SELECT PIK3CA H1047R-MUTANT SOLID TUMORS WILL BE INITIATED IN THE SECOND HALF OF 2026 FOR THE REST OF THE PORTFOLIO, PROGRAMS CONTINUE TO PROGRESS AS PLANNED. ADDITIONAL EXPECTED UPCOMING MILESTONES ACROSS RECURSION'S INTERNAL PIPELINE: REC-1245 (RBM39): ADDITIONAL PHASE 1 DOSE ESCALATION DATA EXPECTED IN 2H26 REC-617 (CDK7): EARLY PHASE 1 SAFETY AND PK COMBINATION DATA EXPECTED IN 1H27 REC-3565 (MALT1): EARLY PHASE 1 SAFETY AND PK MONOTHERAPY DATA EXPECTED IN 1H27 REC-4539 (LSD1): EARLY PHASE 1 SAFETY AND PK MONOTHERAPY DATA EXPECTED IN 2H27 AGENTIC AI IS COMPOUNDING RECURSION'S ADVANTAGE ACROSS BIOLOGY, DESIGN, AND CLINTECH: TARGET DISCOVERY AGENT PAIRS FRONTIER AI REASONING WITH RECURSION'S PROPRIETARY MULTIMODAL MAPS TO SURFACE NOVEL DRUG TARGETS

RECURSION REPORTS SECOND QUARTER FINANCIAL RESULTS; GENENTECH OPTIONS FIRST NEUROSCIENCE TARGET INTO EARLY DISCOVERY PROGRAM

SALT LAKE CITY, UT, AUG. 04, 2026 (GLOBE NEWSWIRE) -- RECURSION (NASDAQ: RXRX), A LEADING CLINICAL-STAGE TECHBIO COMPANY DECODING BIOLOGY TO RADICALLY IMPROVE LIVES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: BANK OF AMERICA 2026 SMID CAP EXECUTIVE INSIGHTS EVENT  TUESDAY, AUGUST 11, 2026 MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE  TUESDAY, SEPTEMBER 15, 2026 WEBCASTS MAY BE FOUND IN THE EVENTS SECTION OF THE RECURSION INVESTOR RELATIONS WEBSITE AT IR.RECURSION.COM . ABOUT RECURSION RECURSION (NASDAQ: RXRX) IS A CLINICAL STAGE TECHBIO COMPANY DECODING BIOLOGY TO RADICALLY IMPROVE LIVES.

RECURSION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SALT LAKE CITY, UT, JULY 31, 2026 (GLOBE NEWSWIRE) -- RECURSION (NASDAQ: RXRX), A LEADING CLINICAL STAGE TECHBIO COMPANY DECODING BIOLOGY TO RADICALLY IMPROVE LIVES, ANNOUNCED THAT ON JULY 27, 2026, THE COMPENSATION COMMITTEE OF RECURSION'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT RESTRICTED STOCK UNIT (RSU) AWARDS COVERING 3,234,866 SHARES OF ITS CLASS A COMMON STOCK IN THE AGGREGATE TO 24 NEW EMPLOYEES UNDER RECURSION'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE 2024 PLAN). EACH AWARD WAS GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEE'S COMMENCEMENT OF EMPLOYMENT WITH RECURSION, OR A SUBSIDIARY OF RECURSION, PURSUANT TO NASDAQ LISTING RULE 5635(C)(4).

RECURSION REPORTS GRANT OF INDUCEMENT AWARDS AS PERMITTED BY THE NASDAQ LISTING RULES

SALT LAKE CITY, UT, JULY 29, 2026 (GLOBE NEWSWIRE) -- SALT LAKE CITY, UT, JULY 29, 2026 (GLOBE NEWSWIRE)  RECURSION (NASDAQ: RXRX), A LEADING CLINICAL STAGE TECHBIO COMPANY DECODING BIOLOGY TO RADICALLY IMPROVE LIVES, ANNOUNCED TODAY IT WILL PROVIDE BUSINESS UPDATES AND REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 5, 2026, BEFORE THE OPEN OF THE FINANCIAL MARKETS. RECURSION WILL HOST AN EARNINGS CALL ON AUG 5, 2026 AT 8:00 AM ET / 6:00 AM MT / 1:00 PM BST.

Recursion Pharmaceuticals, Inc.

RXRX

Price

Financial Reports

No items found.

Press Releases

Recursion Pharmaceuticals, Inc.

RXRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RXRX